| Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer H Borghaei, L Paz-Ares, L Horn, DR Spigel, M Steins, NE Ready, ... New England Journal of Medicine 373 (17), 1627-1639, 2015 | 8750 | 2015 |
| Tumor mutational load predicts survival after immunotherapy across multiple cancer types RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ... Nature genetics 51 (2), 202-206, 2019 | 2489 | 2019 |
| Akt stimulates aerobic glycolysis in cancer cells RL Elstrom, DE Bauer, M Buzzai, R Karnauskas, MH Harris, DR Plas, ... Cancer research 64 (11), 3892-3899, 2004 | 1695 | 2004 |
| Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs MG Kris, BE Johnson, LD Berry, DJ Kwiatkowski, AJ Iafrate, II Wistuba, ... Jama 311 (19), 1998-2006, 2014 | 1623 | 2014 |
| Efficacy and safety of vismodegib in advanced basal-cell carcinoma A Sekulic, MR Migden, AE Oro, L Dirix, KD Lewis, JD Hainsworth, ... New England Journal of Medicine 366 (23), 2171-2179, 2012 | 1493 | 2012 |
| Inhibition of the hedgehog pathway in advanced basal-cell carcinoma DD Von Hoff, PM LoRusso, CM Rudin, JC Reddy, RL Yauch, R Tibes, ... New England Journal of Medicine 361 (12), 1164-1172, 2009 | 1301 | 2009 |
| Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449 CM Rudin, CL Hann, J Laterra, RL Yauch, CA Callahan, L Fu, T Holcomb, ... New England Journal of Medicine 361 (12), 1173-1178, 2009 | 1165 | 2009 |
| Genetic Variants in the UDP-glucuronosyltransferase 1A1 Gene Predict the Risk of Severe Neutropenia of Irinotecan F Innocenti, SD Undevia, L Iyer, P Xian Chen, S Das, M Kocherginsky, ... Journal of Clinical Oncology 22 (8), 1382-1388, 2004 | 1121 | 2004 |
| Molecular determinants of response to anti–programmed cell death (PD)-1 and anti–programmed death-ligand 1 (PD-L1) blockade in patients with non–small-cell lung cancer profiled … H Rizvi, F Sanchez-Vega, K La, W Chatila, P Jonsson, D Halpenny, ... Journal of clinical oncology 36 (7), 633, 2018 | 1067 | 2018 |
| STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung AdenocarcinomaSTK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant LUAC F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ... Cancer discovery 8 (7), 822-835, 2018 | 1037 | 2018 |
| Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer CM Rudin, S Durinck, EW Stawiski, JT Poirier, Z Modrusan, DS Shames, ... Nature genetics 44 (10), 1111-1116, 2012 | 1011 | 2012 |
| Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma RL Yauch, GJP Dijkgraaf, B Alicke, T Januario, CP Ahn, T Holcomb, ... Science 326 (5952), 572-574, 2009 | 959 | 2009 |
| Pneumonitis in patients treated with anti–programmed death-1/programmed death ligand 1 therapy J Naidoo, X Wang, KM Woo, T Iyriboz, D Halpenny, J Cunningham, ... Journal of Clinical Oncology 35 (7), 709, 2017 | 921 | 2017 |
| Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer MD Hellmann, T Nathanson, H Rizvi, BC Creelan, F Sanchez-Vega, ... Cancer cell 33 (5), 843-852. e4, 2018 | 797 | 2018 |
| Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non–Small Cell Lung CancerCombinatorial Epigenetic Therapy for Lung Cancer RA Juergens, J Wrangle, FP Vendetti, SC Murphy, M Zhao, B Coleman, ... Cancer discovery 1 (7), 598-607, 2011 | 658 | 2011 |
| DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration H Kaneko, S Dridi, V Tarallo, BD Gelfand, BJ Fowler, WG Cho, ... Nature 471 (7338), 325-330, 2011 | 656 | 2011 |
| Lung cancer in never smokers: clinical epidemiology and environmental risk factors JM Samet, E Avila-Tang, P Boffetta, LM Hannan, S Olivo-Marston, ... Clinical cancer research 15 (18), 5626-5645, 2009 | 635 | 2009 |
| Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data CM Rudin, JT Poirier, LA Byers, C Dive, A Dowlati, J George, JV Heymach, ... Nature Reviews Cancer 19 (5), 289-297, 2019 | 630 | 2019 |
| Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors L Gandhi, DR Camidge, MR De Oliveira, P Bonomi, D Gandara, D Khaira, ... Journal of clinical oncology 29 (7), 909, 2011 | 611 | 2011 |
| Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid TumorsGDC-0449 Treatment of Advanced or … PM LoRusso, CM Rudin, JC Reddy, R Tibes, GJ Weiss, MJ Borad, ... Clinical cancer research 17 (8), 2502-2511, 2011 | 599 | 2011 |
John T. PoirierAssistant Professor, Perlmutter Cancer Center, NYU Langone HealthVerified email at nyulangone.org
